

OCT 07 2003

New Atty. Dkt. No. 034536-0371
Old Atty. Dkt. No. 038602-1325

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Peng Cho TANG et al.

Title: INDOLINONE COMBINATORIAL LIBRARIES AND RELATED PRODUCTS AND METHODS FOR THE TREATMENT OF DISEASE

Appl. No.: 10/076,621

Filing Date: 02/19/2002

Examiner: Laura Lynne Stockton

Art Unit: 1626

RECEIVED

OCT 09 2003

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

TECH CENTER 1600/2900

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

Re-submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents were previously submitted to the PTO and copies were provided in the parent applications, SN 09/617,529 and 08/915,366. The Examiner has indicated that copies of these references cannot be located in either parent application files.

RELEVANCE OF EACH DOCUMENT

An English translation of the foreign-language documents is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date October 7, 2003

FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5300
Facsimile: (202) 672-5399


Matthew E. Mulkeen
Registration No. 44,250

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton

Attorney Docket Number 034536-0371

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	C1	WO	88/07035	A1	KANEKAUCHI KAGAKU KOGYO KABUSHIKI KAISHA	09-22-1988		
	C2	WO	91/13055	A2	FARMITALIA CARLO ERBA SRL	09-05-1991		
	C3	WO	91/15495	A1	PFIZER INC.	10-17-1991		
	C4	WO	92/07830	A2	PFIZER INC.	05-14-1992		
	C5	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL	11-26-1992		
	C6	WO	92/21660	A1	PFIZER INC.	12-10-1992		
	C7	WO	93/23040	A1	MERCK & CO., INC.	11-25-1993		
	C8	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994		
	C9	WO	94/10202	A1	GENENTECH, INC.	05-11-1994		
	C10	WO	94/14808	A1	FARMITALIA CARLO ERBA SRL	07-07-1994		
	C11	WO	95/01349	A1	FARMITALIA CARLO ERBA SRL	01-12-1995		
	C12	WO	95/14667	A1	PFIZER INC.	06-01-1995		
	C13	WO	95/24190	A2	SUGEN, INC.	09-14-1995		
	C14	WO	96/00226	A1	PHARMACIA S.P.A.	01-04-1996		
	C15	WO	96/16964	A1	PHARMACIA S.P.A.	06-06-1996		
	C16	WO	97/36867	A1	PFIZER, INC.	10-09-1997		
	C17	WO	98/07695	A1	SUGEN, INC.	02-26-1998		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OCT 8 2003
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	C18	WO	98/07835	A2	SUGEN, INC.	02-26-1998		
	C19	WO	98/45708	A1	SUGEN, INC.	10-15-1998		
	C20	WO	98/50356	A1	SUGEN, INC.	11-12-1998		
	C21	WO	98/56376	A1	SUGEN, INC.	12-17-1998		
	C22	DE	878,539		Von FREYBERG, et al.	06-05-1953		X
	C23	DE	2,159,360	A	BAYER AG	06-14-1973		X
	C24	DE	2,159,361	A	BAYER AG	06-14-1973		X
	C25	DE	2,159,362		BAYER AG	06-14-1973		
	C26	DE	2,159,363	A	BAYER AG	06-14-1973		X
	C27	DE	2,321,656	A	COLGATE-PALMOLIVE CO.	11-15-1973		X
	C28	DE	3,310,891	A1	BOEHRINGER MANNHEIM GMBH	09-27-1984		
	C29	DE	3,426,419	A	BOEHRINGER MANNHEIM GMBH	01-23-1986		X
	C30	HU	65452		RICHTER GEDEON BEGYESZETI GYAR RT	06-28-1994		
	C31	EP	0 252 713	B1	PFIZER INC.	01-13-1988		
	C32	EP	0 351 213	A2	LES LABORATOIRES BEECHAM S.A.	01-17-1990		
	C33	EP	0 525 472	A2	FARMITALIA CARLO ERBA SRL	02-03-1993		
	C34	EP	0 566 226	B1	ZENECA LIMITED	10-20-1993		
	C35	EP	0 580 502	B1	ADIR ET COMPAGNIE	01-26-1994		X

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B (PTO)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	3	of	18	Attorney Docket Number	034536-0371
-------	---	----	----	------------------------	-------------

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	C36	EP	0 626 377	B1	SHIONOGI & CO., LTD.	11-30-1994		
	C37	EP	0 662 473	A1	PHARMACIA S.P.A.	07-12-1995		
	C38	EP	0 788 890	A1	AGFA-GEVAERT	08-13-1997		
	C39	FR	2.689.397	A1	ADIR ET COMPAGNIE	10-08-1993		X
	C40	GB	809,691		Roy HULL	03-04-1959		
	C41	GB	835,473		Norman SENIOR	05-18-1960		
	C42	GB	1,384,599		COLGATE-PALMOLIVE CO.	02-19-1975		
	C43	JP	62-29570	A	KANEKA CHEM KK	02-07-1987		X
	C44	JP	62-39564	A	KANEKA CHEM KK	02-20-1987		X
	C45	JP	63-141955	A	KANEKA CHEM KK	06-14-1988		X
	C46	JP	5-58894	A	KANEKA CORP	03-09-1993		X

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C47	ABRAMOVITCH and HEY, "Internuclear cyclisation. Part VIII. Naphth[3:2:1-cd]oxindoles," <i>J. Chem. Soc.</i> 1697-1703 (1954), Strand, London	
	C48	ABRAMOVITCH et al., "A Novel Synthesis of a Cyclic Hydroxamic Acid Involving a Molecular Rearrangement," <i>Chemistry and Industry</i> 44:1871 (1967) © Laporte Industries Limited, Lancashire	
	C49	Beilstein Reg. No. 236050, Beilstein Reference No. 4-21-00-06355	
	C50	AKBASAK and SUNAR-AKBASAK, "Oncogenes: cause or consequence in the development of glial tumors," <i>J. Neurol. Sci.</i> 111:119-133 (1992) © Elsevier Science Publishers	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OCT 07 2003

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton

Attorney Docket Number 034536-0371

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C51	ANDREANI et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25:187-190 (1990)	
	C52	ANDREANI et al., "Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups," <u>Eur. J. Med. Chem.</u> 28:653-657 (1993) © Elsevier, Paris	
	C53	ANDREANI et al., "Synthesis and cardiotonic activity of 2-indolinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 78106 (1990)	
	C54	ANDREANI et al., "Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones," <u>Eur. J. Med. Chem.</u> 27:167-170 (1992) © Elsevier, Paris	
	C55	ANDREANI et al., "Synthesis of lactams with potential cardiotonic activity," <u>Eur. J. Med. Chem.</u> 28:825-829 (1993)	
	C56	ANDREANI et al., "In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones," <u>Arzneimittel-Forschung Drug Research</u> 48:727-729 (1998) 8	
	C57	ARTEAGA et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989) © The American Society for Clinical Investigation, Inc.	
	C58	ARVIDSSON et al., "Tyr-716 in the Platelet-Derived Growth Factor β-Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14:6715-6726 (1994) © The American Society for Microbiology	
	C59	AUTREY and TAHK, "The Synthesis and Stereochemistry of Some Isatylideneacetic Acid Derivatives," <u>Tetrahedron</u> 23:901-917 (1967) © Pergamon Press	
	C60	BAHNER et al., "6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene," <u>J. Med. Chem.</u> 12:722-723 (1969)	
	C61	BAMFIELD et al., "Diels-Alder Reactions of Oxindolylideneacetone," <u>J. Chem. Soc. (C)</u> 1028-1030 (1966)	
	C62	BASERGA, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-930 (1994) © Cell Press	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OCT 07 2003

Substitute for form 1449B/PTO-449B
**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	5	of	18	Attorney Docket Number	034536-0371
-------	---	----	----	------------------------	-------------

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C63	BASERGA, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)	
	C64	Beilstein Reg. No. 235647 (1997)	
	C65	BLAKE and JAQUES, "Anisotropic Effects in α -Substituted Methoxystilbenes," <u>J. Chem. Soc. Perkin II</u> : 1660-1663 (1973) © Pergamon, Oxford	
	C66	BLAKE and JAQUES, "Anisotropic Effects in α -Substituted Methoxystilbenes," <u>Chemical Abstracts</u> , Vol. 80, abstract no. 26692 (1974)	
	C67	BOLEN et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)	
	C68	BOLEN, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993) © MacMillan Press Ltd,	
	C69	BONNER et al., "Structure and Biological Activity of Human Homologs of the <i>raf/mil</i> Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985) © The American Society for Microbiology	
	C70	BORSCHE et al., "Über vielkernige kondensierte Systeme mit heterocyclischen Ringen. XIII," <u>Liebigs Ann. Chem.</u> 550:160-174 (1941)	
	C71	BUZZETTI et al., "Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases," <u>Il Farmaco</u> 48:615-636 (1993)	
	C72	CANCE et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993) © Wiley-Liss, Inc.	
	C73	CANOIRA and RODRIGUEZ, "Synthesis of Oxindole Derivatives from N-Alkenyl- α -Chloroanilides with Zero-Valent Nickel Complex," <u>J. Heterocyclic Chem.</u> 22:1511-1518 (1985)	
	C74	CARPENEDO et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs," <u>Analytical Biochemistry</u> 244:74-79 (1997) © Academic Press, Inc.	
	C75	CHAO, "Growth Factor Signaling: Where Is the Specificity?" <u>Cell</u> 68:995-997 (1992) © Cell Press	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OCT 07 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>REMAILED 10/07/03</i>	
(use as many sheets as necessary)				<i>REMAILED 10/07/03</i>	
Sheet	6	of	18	Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C76	CHATDEN et al., "Substituted Oxindoles. Part VI. Polarographic Reduction of Substituted <i>trans</i> -3-Benzylideneindol-2(3H)-ones," <u>J. Chem. Soc. Perkin II</u> : 469-473 (1973)	
	C77	CHEN et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ -Aminobutyric Acid Elicted Chloride Current of Snail Central Neuron," <u>Chinese Journal of Physiology</u> 40:149-156 (1997)	
	C78	CLAESSON-WELSH, "Signal Transduction by the PDGF Receptors," <u>Progress in Growth Factor Research</u> 5:37-54 (1994) © Elsevier Science Ltd.	
	C79	CODA et al., "(Z)- and (E)-Arylidene-1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies," <u>J. Chem. Soc. Perkin Trans. II</u> : 615-619 (1984)	
	C80	CODA et al., "3-(4-methylbenzylidene)-1,3-dihydroindol-2-one," <u>Journal of the Chemical Society, Perkin Transactions 2</u> 4:615-620 (1984) DATABASE CROSSFIRE, Beilstein Reference No. 6-21	
	C81	COPPOLA et al., "A Functional Insulin-Like Growth Factor I Receptor Is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994) © The American Society for Microbiology	
	C82	DAISLEY and WALKER, "Thin-layer chromatographic separation of some substituted 3-benzylidine-indol-2(3H)-ones," <u>J. Chromatography</u> 100:240-242 (1974) © Elsevier Scientific Publishing Company	
	C83	DAMIANI et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48:1155-1161 (1994) © Elsevier Science Ltd.	
	C84	DATI et al., "Inhibition of c-erbB-2 oncogene expression by estrogens in human breast cancer cells," <u>Oncogene</u> 5:1001-1006 (1990)	
	C85	DAVIS et al., "Synthesis and Microbiological Properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16:1043-1045 (1973) © American Chemical Society	
	C86	DE VRIES et al., "The fms-Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991 (1992)	
	C87	DECKER and LOHMANN-MATTHES, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988) © Elsevier	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OCT 07 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C88	DICKSON et al., "13. Tyrosine kinase receptor - nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992) © Kluwer Academic Publishers	
	C89	ELLIOTT and RIVERS, "Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride," <u>J. Med. Chem.</u> 29:2438-2440 (1964)	
	C90	ELLIOTT et al., "1-methyl-2-(3-oxindolidenmethyl)-pyridinium," <u>Journal of Organic Chemistry</u> 29:2438-2440 (1964) DATABASE CROSSFIRE, Beilstein Reference No. 5-24	
	C91	FANTL et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules That Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992) © Cell Press	
	C92	FENDLY et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product, <u>Cancer Research</u> 50:1550-1558 (1990); © American Association for Cancer Research	
	C93	FERRARA and HENZEL, "Pituitary Follicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989) © Academic Press, Inc.	
	C94	FINGL and WOODBURY, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) © MacMillan Publishing Co. Inc.	
	C95	FLOEGE et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro</i> and <i>in vivo</i> ," <u>Kidney International</u> 43:S47-S54 (1993) © International Society of Nephrology	
	C96	FLOEGE et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," <u>Kidney International</u> 43:369-380 (1993) © International Society of Nephrology	
	C97	FOLKMAN and SHING, "Angiogenesis," <u>J. Biol. Chem.</u> 267:10931-10934 (1992) © The American Society for Biochemistry and Molecular Biology	
	C98	FOLKMAN, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)	
	C99	FOLKMAN, "Tumor Angiogenesis: Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OCT 07 2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C100	FOULKMAN, "What is the Evidence that Tumors are Angiogenesis Dependent?" <u>Journal of the National Cancer Institute</u> 82:4-6 (1990)	
	C101	GAZIT et al., "Tyrphostins. 2. Heterocyclic and α -Substituted Benzylidene malononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2/neu Tyrosine Kinases," <u>J. Med. Chem.</u> 34:1896-1907 (1991) © Am. Chem. Soc.	
	C102	GENNARO (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)	
	C103	GOLDRING and GOLDRING, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)	
	C104	GOTTARDIS et al., "Estradiol-Stimulated Growth of MCF-7 Tumors Implanted in Athymic Mice: A Model to Study the Tumorstatic Action of Tamoxifen," <u>J. Steroid Biochem.</u> 30:311-314 (1988) © Pergamon Press	
	C105	GRAZIANI et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268:9165-9168 (1993) © American Society for Biochemistry and Molecular Biology	
	C106	HEWGILL and STEWART, "Phenanthrene-4,5-quinones: a Synthesis of Morphenol," <u>J. Chem. Soc. Perkin Trans. I</u> :1305-1311 (1988)	
	C107	HODGES et al., "Chemical and biological properties of some oxindolidyl-3-methines," <u>Canadian J. Chemistry</u> 46:2189-2194 (1968)	
	C108	HONEGGER et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987) © Cell Press	
	C109	HOUBEN-WEYL, "Substance Index," <u>Cyclic Compounds V Bicyclic Compounds 1</u> , E231:834-1018 (1999)	
	C110	HOUCK et al., "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Biol. Chem.</u> 267:26031-26037 (1992) © American Society for Biochemistry and Molecular Biology, Inc.	
	C111	HOWARD, Harry R., "Lactam Derivatives," U.S. Provisional Patent Application Number 60/015134	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OCT 07 2003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C112	HOWARD et al., "Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-acetic acids," <u>Eur. J. Med. Chem.</u> 27:779-789 (1992) © Elsevier, Paris	
	C113	HU et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12:981-990 (1992) copyright Am. Soc. Microbiol.	
	C114	IJAZ et al., "The Conversion of α, β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>J. Chem. Res. (S)</u> : 116 (1990)	
	C115	IJAZ et al., "The Conversion of α, β -Dinitrostyrenes into Indoles and the Preparation of Oxindole Quinones," <u>Chemical Abstracts</u> , Vol. 113, abstract no. 93739 (1990)	
	C116	JELLINEK et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994) © American Chemical Society	
	C117	KASHISHIAN and COOPER, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase C γ 1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993) © The American Society for Cell Biology	
	C118	KASHISHIAN et al., "Phosphorylation sites in the PDGF receptor with different specificities for binding GAP and PI3 kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11:1373-1382 (1992)	
	C119	KATO et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993) © Elsevier Science	
	C120	KATRITZKY et al., "Color and Constitution. Part 8[1]. Some Novel Dyestuffs Containing Indoxyl Residues," <u>J. Heterocyclic Chem.</u> 25:1287-1292 (1988)	
	C121	KAZLAUSKAS et al., "The 64-kDa protein that associates with the platelet-derived growth factor receptor β subunit via Tyr-1009 is the SH2-containing phosphotyrosine phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)	
	C122	KENDALL and THOMAS, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)	
	C123	KHALIL and ABDEL-RAHMAN, "Synthesis of New Mero- and Asymmetrical Pyrazolo-Monomethine Cyanine Dyes," <u>J. Indian Chem. Soc.</u> 54:904-907 (1977) © The Indian Chemical Society	

Examiner
SignatureDate
Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 10 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C124	KIM et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth <i>in vivo</i> ," <u>Nature</u> 362:841-844 (1993)	
	C125	KINSELLA et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992) © Academic Press, Inc.	
	C126	LAGSBRUN and SOKER, "VEGF/VPF: the angiogenesis factor found?" <u>Current Biology</u> 3:699-702 (1993) <u>8Current Biology</u>	
	C127	KOBAYASHI et al., "Anti-tumor Activity of Indole Derivatives," <u>Yakugaku Zasshi</u> 97:1033-1039 (1977)	
	C128	KOCH et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)	
	C129	KOHLER and MILSTEIN, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> 256:495-497 (1975)	
	C130	KOMADA and KITAMURA, "The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)	
	C131	KORC et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer Is Associated with Concomitant Increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992) copyright The American Society for Clinical Investigation, Inc.	
	C132	KORZENIEWSKI and CALLEWAERT, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313-320 (1983) © Elsevier Science Publishers	
	C133	KOVAC and STETNOVA, "Furan derivatives. LXXX. Synthesis and properties of substituted furfurylidenoindoles," <u>Chem. rvesu</u> 30:484-492 (1976)	
	C134	KRUEGER and SAITO, "A human transmembrane protein-tyrosine-phosphatase, PTPb, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases," <u>Proc. Natl. Acad. Sci. USA</u> 89:7417-7421 (1992)	
	C135	KUMABE et al., "Amplification of α-platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OCT 07 2003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 11 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C136	LAROCK and BABU, "Synthesis of Nitrogen Heterocycles via Palladium-catalyzed Intramolecular Cyclization," <u>Tetrahedron Letters</u> 28:5291-5294 (1987) copyright Pergamon Journals Ltd.	
	C137	LEE and DONOGHUE, "Intracellular Retention of Membrane-Anchored v-sis Protein Abrogates Autocrine Signal T transduction," <u>J. Cell. Biol.</u> 118:1057-1070 (1992) © The Rockefeller University Press	
	C138	LEVITZKI and GAZIT, "Tyrosine Kinase Inhibition: An Approach to Drug Development," <u>Science</u> 267:1782-1788 (1995)	
	C139	MAASS et al., "Viral Resistance to the Thiazolo-Iso-Indolinones, a New Class of Nonnucleoside Inhibitors of Human Immunodeficiency Virus Type 1 Reverse Transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37:2612-2617 (1993) © American Society for Microbiology	
	C140	MACAULAY et al., "Autocrine Function for Insulin-like Growth Factor I in Human Small Cell Lung Cancer Cell Lines and Fresh Tumor Cells," <u>Cancer Research</u> 50:2511-2517 (1990)	
	C141	MARIANI et al., "Inhibition of angiogenesis by FCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)	
	C142	MARTIN-LEON et al., "On the Cyclization to the Elusive Amino-4H-pyran Ring Some New Facts," <u>Liebigs Ann. Chem.</u> 101-104 (1990) copyright VCH Veilaxs of Sellschaft mbH © VCH	
	C143	MILLAUER et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993) © Cell Press	
	C144	MIRAND et al., "A Synthetic Entry in the Aristotelia Alkaloids," <u>J. Org. Chem.</u> , 47:4169-4170 (1982)	
	C145	MOHAMMADI et al., "Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors," <u>Science</u> 276:955-960 (1997) © American Association for the Advancement of Science	
	C146	MORETO et al., "Study of the Laxative Properties of the Disodium Salt of the Sulfuric Diester of 3,3 Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (DAN-603) in the Rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976) © North-Holland Publishing Company	
	C147	MORETO et al., "3,3-Bis-(4-Hydroxyphenyl)-7-Methyl-2-Indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin," <u>Arzneimittel-Forschung Drug Research</u> 29:1561-1564 (1979)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OCT 07 2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C148	MORRISON et al., "Signal Transduction From Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increase Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85:8855-8859 (1988)	
	C149	MOSMANN, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983) © Elsevier Publishers B.V.	
	C150	NEBER and RÖCKER, "On the action of benzaldehydes on the free o-aminophenylacetic acid (II)," <u>Chem. Ber.</u> 56:1710-1716 (1923) (GERMAN AND ENGLISH TRANSLATION)	
	C151	NISHIMURA et al., "Two Signaling Molecules Share a Phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993)	
	C152	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>J. Med. Chem.</u> 14:921-925 (1971)	
	C153	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 1. Fluorine-Containing 3- and 6-Substituted 9-Phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 765, abstract no. 21121 (1972)	
	C154	NODIFF et al., "Antimalarial Phenanthrene Amino Alcohols. 3. Halogen-containing 9-phenanthrenemethanols," <u>Chemical Abstracts</u> , Vol. 83, abstract no. 188214 (1975)	
	C155	OSBORNE et al., "Effect of Estrogens and Antiestrogens on Growth of Human Breast Cancer Cells in Athymic Nude Mice," <u>Cancer Research</u> 45:584-590 (1985)	
	C156	O'SULLIVAN and ROTHERY, "The Preparation and Possible Clinical Significance of 4'-Dialkylaminoisoindogenides," <u>Clinica Chimica Acta</u> 62:181-182 (1975) © Elsevier Scientific Publishing Company	
	C157	OZZELLO and SORDAT, "Behavior of Tumors Produced by Transplantation of Human Mammary Cell Lines in Athymic Nude Mice," <u>Eur. J. Cancer</u> 16:553-559 (1980)	
	C158	PAVLENKO et al., "Introduction of aminomethyl groups into heterocyclic CH-acid molecules," <u>Dopov. Akad. Nauk Ukr Rsr, Ser. B: Geol., Khim. Biol. Nauki</u> 7:64-66 (1980)	
	C159	PLATE et al., "Vascular endothelial growth factor is potential tumor angiogenesis factor in human gliomas <i>in vivo</i> ," <u>Nature</u> 359:845-848 (1992)	
	C160	PLOWMAN et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7:334-339 (1994)	

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OCT 07 2003
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C161	QUINN et al., "Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)	
	C162	ROZAKIS-ADCOCK et al., "Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases," <u>Nature</u> 360:689-692 (1992)	
	C163	RUVEDA and GONZALEZ, "Geometric isomerism in benzylideneoxindoles," <u>Spectrochimica Acta</u> 26A:1275-1277 (1970)	
	C164	RYGAARD and POVLSEN, "Heterotransplantation of a Human Malignant Tumour to 'Nude' Mice," <u>Acta Path. Microbiol. Scand.</u> 77:758-760 (1969)	
	C165	SAITO and STREULI, "Molecular Characterization of Protein Tyrosine Phosphatases," <u>Cell Growth & Differentiation</u> 2:59-65 (1991) © Molecular Biology Journal of the American Association for Cancer Research	
	C166	SANDBERG-NORDQVIST et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)	
	C167	SCHINDLER et al., "Über Dibenz[b,f]-azocin-Derivate," <u>Helvetica Chimica Acta</u> 49:985-989 (1966)	
	C168	SCHLESSINGER and ULLRICH, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992) © Cell Press	
	C169	SCHNIERLE et al., "Vilsmeier-Reaktion mit Pyrrol- und Pyrrolon-Derivaten," <u>Liebigs Ann. Chem.</u> , 715:90-97 (1968)	
	C170	SCHUCHTER et al., "Successful Treatment of Murine Melanoma with Bryostatin 1," <u>Cancer Research</u> 51:682-687 (1991)	
	C171	SEIBERT et al., "Clonal Variation of MCF-7 Breast Cancer Cells <u>in Vitro</u> and in Athymic Nude Mice," <u>Cancer Research</u> 43:2223-2234 (1983)	
	C172	SHAFIE and GRANTHAM, "Role of Hormones in the Growth and Regression of Human Breast Cancer Cells (MCF-7) Transplanted Into Athymic Nude Mice," <u>J. Natl. Cancer Institute</u> 67:51-56 (1981)	
	C173	SHIBUYA et al., "Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (fit) closely related to the fms family," <u>Oncogene</u> 5:519-524 (1990)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OCT 07 2003

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 14 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C174	SHIRAISHI et al., "Specific inhibitors of Tyrosine-Specific Protein Kinase, Synthetic 4-Hydroxycinnamamide Derivatives," <u>Biochemical and Biophysical Research Communications</u> 147:322-328 (1987) Academic Press	
	C175	SHIRAISHI et al., "Specific Inhibitors of Tyrosine-specific Protein Kinases: Properties of 4-Hydroxycinnamamide Derivatives <i>in Vitro</i> ," <u>Cancer Research</u> 49:2374-2378 (1989)	
	C176	SHWEIKI et al., "Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis," <u>Nature</u> 359:843-845 (1992)	
	C177	SINGH et al., "Indolinone Derivatives as Potential Antimicrobial Agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989) copyright VEB Gustav Fischer Verlag Jena	
	C178	SINGH et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxospiro (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)	
	C179	SKEHAN et al., "New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening," <u>J. Natl. Cancer Inst.</u> 82:1107-1112 (1990)	
	C180	SLAMON et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)	
	C181	SOLDI et al., "Platelet-Activating Factor (PAF) Induces the Early Tyrosine Phosphorylation of Focal Adhesion Kinase (p125 ^{FAK}) in Human Endothelial Cells," <u>Oncogene</u> 13:515-525 (1996) copyright Stockton Press	
	C182	SONGYANG et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993) Cell Press	
	C183	SONGYANG et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fes/fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994) © American Society for Microbiology	
	C184	SPADA, et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5:805-817 (1995) © Ashley Publications	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OCT 07 2003

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 15 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C185	STETINOVA et al., "Stereochemistry and Photoisomerisation of Furfurylideneoxindoles," <u>Collection Czechoslov. Chem. Commun.</u> 42:2201-2206 (1977)	
	C186	STOLLE, <u>Beilstein Reg. No. 273650, J. Prakt. Chem.</u> , Vol. 2, page 128 (1930)	
	C187	SUMPTER and MILLER, "Chapter IV – Oxindole," in <u>Heterocyclic Compounds With Indole and Carbazole Systems</u> , 8 Interscience Publishers, Inc., New York, pp. 134-153 (1954)	
	C188	SUN et al., "Synthesis and Biological Evaluations of 3-Substituted Indolin-2-ones: A Novel Class of Tyrosine Kinase Inhibitors That Exhibit Selectivity toward Particular Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> 41:2588-2603 (1998) ©The American Chemical Society	
	C189	SUPERTI-FURGA et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech.</u> 14:600-605 (1996)	
	C190	SUPERTI-FURGA et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993) © Oxford University Press	
	C191	TACCONI and MARINONE, "Preparazione e caratteristiche di alcuni 3-ossindolidenderivati," <u>Ricerca Scientifica</u> 38:1239-1244 (1968)	
	C192	TACCONI et al., "(Z)- and (E)-3-Alkylidene-1,3-dihydroindol-2-ones: Influence of Configuration on the Transmission of the Inductive Effect to the Carbonyl Group," <u>J.C.S. Perkin II</u> 150-154 (1976)	
	C193	TAKANO et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits Protein Kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)	
	C194	THOMPSON et al., "Facile Dimerisation of 3-Benzylideneindoline-2-thiones," <u>J. Chem. Soc. Perkin Trans. (I)</u> 1835-1837 (1993)	
	C195	TORP et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>APMIS</u> 100:713-719 (1992)	
	C196	TRAXLER, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997) © Ashley Publications Ltd.	
	C197	TREIBS et al., "Uber Isoindigoide Farbstoffe der Pyrrol-Reihe," <u>Liebigs Ann. Chem.</u> , 702:112-130 (1967)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/076,621
(use as many sheets as necessary)				Filing Date	02/19/2002
Sheet	16	of	18	First Named Inventor	Peng Cho TANG
				Group Art Unit	1626
				Examiner Name	Laura Stockton
				Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	C198	TROST et al. (eds.), "Comprehensive Organic Synthesis," <u>Selectivity, Strategy & Efficiency in Modern Organic Chemistry</u> , 4:478 (1991)			
	C199	TSAI et al., "The Effect of 3,3-Di-Pyridyl Methyl-1-Phenyl-2-Indolinone on the Nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31:943-947 (1992) © Pergamon Press			
	C200	TUZI et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1991)			
	C201	TWAMLEY-STEIN et al., "The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells," <u>Proc. Natl. Acad. Sci. USA</u> 90:7696-7700 (1993)			
	C202	ULLRICH and SCHLESSINGER, "Signal Transduction by Receptors with Tyrosine Kinase Activity," <u>Cell</u> 61:203-212 (1990) copyright Cell Press			
	C203	VAISMAN et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990) © The American Society for Biochemistry and Molecular Biology			
	C204	VARMA and GUPTA, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989) © The Indian Chemical Society			
	C205	VOLLER et al., "Ch. 45 – Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980); © American Society for Microbiology			
	C206	von DOBENECK et al., "α,β'-Diindolylmethane und-methene. Der Urorsein-Chromophor," <u>Zur Chemie des Indols</u> , VI:1347-1357 (1969)			
	C207	WAHL et al., "3-benzilidene-5-methyl-1,3-dihydroindol-2-one," <u>Ann. Chim.</u> 350 (1926), DATABASE CROSSFIRE, Beilstein Reference No. 2-21-00-00290			
	C208	WAHL et al., "Chimie Organique - Sur les iso-indogenides," <u>C.R. Hebd. Seances Acad. Sci.</u> 149:132-134 (1909)			
	C209	WAHL, Beilstein Reg. No. 191439, <u>Bull. Soc. Chim. Fr.</u> , page 1038 (1909)			
	C210	WALKER, "Synthesis of a α-(p-Aminophenyl)- and α-(p-Chlorophenyl)-β-aryl-propionitriles by Catalytic Reduction of Stilbenenitriles," <u>J. Med. Chem.</u> 8:583-588 (1965)			

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 17 of 18

Complete if Known

Application Number	10/076,621
Filing Date	02/19/2002
First Named Inventor	Peng Cho TANG
Group Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	034536-0371

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	C211	WALKER et al., "Synthesis of New 3-(Pyridylmethylene)-, 3-(Pyridylmethyl)-, 3-(Piperidylmethyl)-, and 3-(β -Alkylaminoethyl)-2-indolinones. The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8:626-637 (1965)	
	C212	WALKER et al., "The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> , 8(5):626-637 (1995)	
	C213	WARRI et al., "Estrogen Suppression of erbB2 Expression is Associated with Increased Growth Rate of ZR-75-1 Human Breast Cancer Cells <u>In Vitro</u> and in Nude Mice," <u>Int. J. Cancer</u> 49:616-623 (1991) 8 Wiley-Leiss, Inc.	
	C214	WEIDNER et al., "Tumor Angiogenesis and Metastasis – Correlation in Invasive Breast Carcinoma," <u>New England J. Medicine</u> 324:1-7 (1991) 8 Massachusetts Medical Society	
	C215	WINKELMANN et al., "Chemotherapeutically Active Nitro Compounds: 4. 5-Nitroimidazoles (Part I)," <u>Arzneim.-Forsch./Drug Res.</u> 27:2251-2263 (1977)	
	C216	WRIGHT et al., "Cyclic Hydroxamic Acids Derived from Indole," <u>J. Am. Chem. Soc.</u> 78:221-224 (1956)	
	C217	WRIGHT et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)	
	C218	WRIGHT, Beilstein Reg. No. 244658, <u>J. Amer. Chem. Soc.</u> , 78:221-224 (1956)	
	C219	WRIGHT, Beilstein Reg. No. 235900, <u>J. Amer. Chem. Soc.</u> , 78:221-224 (1956)	
	C220	YOUNG and BABBITT, "2-(2-Methyl-3-indolyl)-1,4-benzoquinone, a Reversible Redox Substrate at the Carbon-Paste Electrode in Acidic Aqueous-Ethanolic Media," <u>J. Org. Chem.</u> 47:1571-1572 (1982) copyright Am. Chem. Soc.	
	C221	ZAMAN et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β -Receptor (β -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57:57-64 (1999) 8Elsevier Science Inc.	
	C222	ZHANG et al., "Microtubule Effects of Welwistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-234 (1996) 8The American Society for Pharmacology and Experimental Pharmacetics	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

OCT 9 7 2003

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 18 of 18

Complete if Known

Application Number 10/076,621

Filing Date 02/19/2002

First Named Inventor Peng (

Group Art Unit 1626

Examiner Name Laura Stockton

Attorney Docket Number 034536-0371

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.